 Phospholipases A2, Secretory
"Phospholipases A2, Secretory" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subcategory of phospholipases A2 that are secreted from cells. They are 14 kDa proteins containing multiple disulfide-bonds and access their substrate via an interfacial binding site that interacts with phospholipid membranes. In addition specific PHOSPHOLIPASE A2 RECEPTORS can bind to and internalize the enzymes.
| Descriptor ID |
D054497
|
| MeSH Number(s) |
D08.811.277.352.100.680.750.937.750
|
| Concept/Terms |
Phospholipases A2, Secretory- Phospholipases A2, Secretory
- Secretory Phospholipases A2
- Secreted Phospholipases A2
- sPLA2s
- sPLA(2)
- SPLA2 Phospholipases
- Phospholipases, SPLA2
- Phospholipases A2, Secreted
- Secretory Phospholipase A2
- Phospholipase A2, Secretory
|
Below are MeSH descriptors whose meaning is more general than "Phospholipases A2, Secretory".
Below are MeSH descriptors whose meaning is more specific than "Phospholipases A2, Secretory".
This graph shows the total number of publications written about "Phospholipases A2, Secretory" by people in this website by year, and whether "Phospholipases A2, Secretory" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 2 | 0 | 2 | | 2012 | 4 | 0 | 4 | | 2013 | 2 | 0 | 2 | | 2014 | 1 | 2 | 3 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Phospholipases A2, Secretory" by people in Profiles.
-
Halpern AL, Kohtz PD, Rove JY, Ao L, Meng X, Fullerton DA, Weyant MJ. Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma. Mol Cell Biochem. 2019 Jun; 456(1-2):145-156.
-
Bennett DT, Deng XS, Yu JA, Bell MT, Mauchley DC, Meng X, Reece TB, Fullerton DA, Weyant MJ. Cancer stem cell phenotype is supported by secretory phospholipase A2 in human lung cancer cells. Ann Thorac Surg. 2014 Aug; 98(2):439-45; discussion 445-6.
-
Heneghan AF, Pierre JF, Gosain A, Kudsk KA. IL-25 improves luminal innate immunity and barrier function during parenteral nutrition. Ann Surg. 2014 Feb; 259(2):394-400.
-
Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014 Jan 15; 311(3):252-62.
-
Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, Cooper JA, Palmen J, Hubacek JA, Carruthers KF, Horne BD, Brunisholz KD, Mega JL, van Iperen EPA, Li M, Leusink M, Trompet S, Verschuren JJW, Hovingh GK, Dehghan A, Nelson CP, Kotti S, Danchin N, Scholz M, Haase CL, Rothenbacher D, Swerdlow DI, Kuchenbaecker KB, Staines-Urias E, Goel A, van 't Hooft F, Gertow K, de Faire U, Panayiotou AG, Tremoli E, Baldassarre D, Veglia F, Holdt LM, Beutner F, Gansevoort RT, Navis GJ, Mateo Leach I, Breitling LP, Brenner H, Thiery J, Dallmeier D, Franco-Cereceda A, Boer JMA, Stephens JW, Hofker MH, Tedgui A, Hofman A, Uitterlinden AG, Adamkova V, Pitha J, Onland-Moret NC, Cramer MJ, Nathoe HM, Spiering W, Klungel OH, Kumari M, Whincup PH, Morrow DA, Braund PS, Hall AS, Olsson AG, Doevendans PA, Trip MD, Tobin MD, Hamsten A, Watkins H, Koenig W, Nicolaides AN, Teupser D, Day INM, Carlquist JF, Gaunt TR, Ford I, Sattar N, Tsimikas S, Schwartz GG, Lawlor DA, Morris RW, Sandhu MS, Poledne R, Maitland-van der Zee AH, Khaw KT, Keating BJ, van der Harst P, Price JF, Mehta SR, Yusuf S, Witteman JCM, Franco OH, Jukema JW, de Knijff P, Tybjaerg-Hansen A, Rader DJ, Farrall M, Samani NJ, Kivimaki M, Fox KAA, Humphries SE, Anderson JL, Boekholdt SM, Palmer TM, Eriksson P, Par? G, Hingorani AD, Sabatine MS, Mallat Z, Casas JP, Talmud PJ. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2013 Nov 19; 62(21):1966-1976.
-
Sadaria MR, Yu JA, Meng X, Fullerton DA, Reece TB, Weyant MJ. Secretory phospholipase A2 mediates human esophageal adenocarcinoma cell growth and proliferation via ERK 1/2 pathway. Anticancer Res. 2013 Apr; 33(4):1337-42.
-
Yu JA, Kalatardi S, Dohse J, Sadaria MR, Meng X, Fullerton DA, Weyant MJ. Group IIa sPLA2 inhibition attenuates NF-?B activity and promotes apoptosis of lung cancer cells. Anticancer Res. 2012 Sep; 32(9):3601-7.
-
Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, Bash D, Hislop C. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012 Feb; 26(1):71-5.
-
Yu JA, Sadaria MR, Meng X, Mitra S, Ao L, Fullerton DA, Weyant MJ. Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A2 inhibition. J Thorac Cardiovasc Surg. 2012 Feb; 143(2):405-11.
-
Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, Bao W, Schwartz GG, Tsimikas S. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation. 2012 Feb 14; 125(6):757-66.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|